Explore more publications!
Eureka State News
Got News to Share?

Eureka State News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Eureka State News.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 7, 2025

Naval Aviator Turned NPS Doctoral Student Earns National Recognition for Applied Quantum Research
December 7, 2025

Naval Aviator Turned NPS Doctoral Student Earns National Recognition for Applied Quantum Research

Indeterminate EIN Presswire
PROPSTORE ACHIEVES $10.2 MILLION IN DAY ONE RESULTS AS LONDON ENTERTAINMENT MEMORABILIA AUCTION OPENS STRONGLY
December 7, 2025

PROPSTORE ACHIEVES $10.2 MILLION IN DAY ONE RESULTS AS LONDON ENTERTAINMENT MEMORABILIA AUCTION OPENS STRONGLY

Indeterminate EIN Presswire
'The Breaking of Time' by J.J. Hebert Hits No. 1 Amazon Best Seller & Top New Release
December 7, 2025

'The Breaking of Time' by J.J. Hebert Hits No. 1 Amazon Best Seller & Top New Release

Indeterminate EIN Presswire
COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.
December 7, 2025

COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.

Indeterminate EIN Presswire
Disruptive Futures Institute Names Metaruptions 2026 Word of the Year & Launches Roger Spitz’s Visionary Keynote Series
December 7, 2025

Disruptive Futures Institute Names Metaruptions 2026 Word of the Year & Launches Roger Spitz’s Visionary Keynote Series

Indeterminate EIN Presswire
Gurjit Singh Chadha releases transformative New Book: Unraveling Your True Self – Discovering the Essence of 'Who Am I?'
December 7, 2025

Gurjit Singh Chadha releases transformative New Book: Unraveling Your True Self – Discovering the Essence of 'Who Am I?'

Indeterminate EIN Presswire
Zensa Skin Care Expands Its Presence in Aesthetic Clinics Nationwide
December 7, 2025

Zensa Skin Care Expands Its Presence in Aesthetic Clinics Nationwide

Indeterminate EIN Presswire
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 7, 2025

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Indeterminate GlobeNewswire
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 7, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Indeterminate GlobeNewswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Indeterminate GlobeNewswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 7, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Indeterminate GlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 7, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions